SOAT1 and Alzheimer disease: Some of these molecules have gained a major role in the treatment of chronic and disabling skin diseases that were not previously controlled with standard treatments, such as anti-IL-4/13 in AD, anti-TNF-α in HS or JAK inhibitors in AA, generating a paradigm shift in the therapeutic armamentarium of dermatology.44, 152, 153 In addition, advances in the understanding of pathophysiology of these diseases have facilitated targeted therapy approaches in inflammatory pathways such as the blockade of JAK-STAT dependent cytokines IL-5, IL-6, IL-10, and IL-13 in DIHS/DRESS.132